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Background: We previously demonstrated that patients with meta-
static KRAS mutant lung cancers have a shorter survival compared 
with patients with KRAS wild-type cancers. Recent reports have 
suggested different clinical outcomes and distinct activated signal-
ing pathways depending on KRAS mutation subtype. To better under-
stand the impact of KRAS mutation subtype, we analyzed data from 
677 patients with KRAS mutant metastatic lung cancer.
Methods: We reviewed all patients with metastatic or recurrent lung can-
cers found to have KRAS mutations over a 6-year time period. We evalu-
ated the associations among KRAS mutation type, clinical factors, and 
overall survival in univariate and multivariate analyses. Any significant 
findings were validated in an external multi-institution patient dataset.
Results: Among 677 patients with KRAS mutant lung cancers (53 at 
codon 13, 624 at codon 12), there was no difference in overall survival 
for patients when comparing KRAS transition versus transversion 
mutations (p = 0.99), smoking status (p = 0.33), or when comparing 
specific amino acid substitutions (p = 0.20). In our dataset, patients 
with KRAS codon 13 mutant tumors (n = 53) had shorter overall sur-
vival compared with patients with codon 12 mutant tumors (n = 624) 
(1.1 versus 1.3 years, respectively; p = 0.009), and the findings were 
confirmed in a multivariate Cox model controlling for age, sex, and 
smoking status (hazard ratio: 1.52, 95% confidence interval: 1.11–
2.08; p = 0.008). In an independent validation set of tumors from 
682 patients with stage IV KRAS mutant lung cancers, there was no 
difference in survival between patients with KRAS codon 13 versus 
codon 12 mutations (1.0 versus 1.1 years, respectively; p = 0.41).
Conclusions: Among individuals with KRAS mutant metastatic lung 
cancers treated with conventional therapy, there are no apparent dif-
ferences in outcome based on KRAS mutation subtype.
Key Words: Lung cancer, KRAS, Prognostic markers, Adenocarcinoma, 
Metastatic.
(J Thorac Oncol. 2015;10: 431–437)
RAS mutations are identified in 25%–30% of lung adeno-carcinomas; the vast majority is KRAS mutations occur-
ring at codon 12 or 13. In small cohorts, specific point 
mutations such as G12V and G12R and KRAS codon 12 have 
been associated with trends toward poorer outcomes.1–3 It is 
difficult to make definitive conclusions about KRAS muta-
tions as a prognostic marker as published studies use differ-
ing molecular diagnostic techniques, comparing populations 
and endpoints.1–9 Moreover, the discovery of other oncogenes 
such as epidermal growth factor receptor (EGFR) and ALK 
with potent targeted therapy available10,11 must be taken into 
account when evaluating the prognostic significance of any 
biomarker as these discoveries highlight the heterogeneity of 
the KRAS wild-type designation.
Studies report superior survival for never-smokers 
compared with current or ex-smokers,12 which may be due 
to a differing distribution of oncogenic drivers with KRAS 
more frequent in smokers and EGFR and ALK alterations 
more common in never smokers.13 There are no differences 
in survival between current/former smokers and never smok-
ers when their tumors harbor the same driver oncogene.13 
Transversion mutations refer to the substitution of a purine 
nucleotide to a pyrimidine, or vice versa. Transitions refer 
to a purine to purine or pyrimidine to pyrimidine nucleotide 
change. Within KRAS, transversion mutations are more com-
mon in current or ex-smokers, and never-smokers have a 
higher frequency of transition mutations.14,15 Data with regard 
to outcomes for KRAS transition versus transversion muta-
tions are conflicting.2,16
In colorectal cancer, the specific KRAS point muta-
tion present may be a prognostic and predictive marker with 
G12V conveying an increased risk of disease recurrence and 
death.17–19 Patients with KRAS codon 12 mutant colorectal 
tumors had shorter overall survival compared with patients 
with KRAS codon 13 mutant tumors.19 The biologic basis of 
these findings is not fully understood but may be related to 
differences in downstream signaling or protein expression.20,21 
In colorectal cancer, KRAS mutation status has been validated 
as a predictive marker of response to EGFR-targeted therapies 
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with the presence of a KRAS mutation predicting a lack of 
response to cetuximab or panitumumab,22 and newer data raise 
the possibility that specific KRAS point mutations may induce 
differential responses to EGFR-directed therapies.23
In lung cancers, the predictive utility of KRAS mutations 
as a marker of response to both targeted therapy and standard 
cytotoxic chemotherapy has been of great interest (Table 1). 
The presence of a KRAS mutation suggests a lack of response 
to EGFR tyrosine kinase inhibitors,24,25 but has not been help-
ful in selecting patients for treatment with EGFR monoclonal 
antibodies.26,27 In the BATTLE trial, patients with KRAS G12C 
and G12V mutant lung cancers were found to have a shorter pro-
gression-free survival than other KRAS genotypes with certain 
targeted therapies such as erlotinib, vandetanib, bexarotene, and 
sorafenib.28 Recent data suggest that the specific KRAS muta-
tion present may predict response to adjuvant chemotherapy 
TABLE 1. KRAS as a Predictive Marker
Author Trial Design Treatment % KRAS Mutant Findings
Rodenhuis et al.30 Single arm phase II of patients with 
metastatic disease
Carboplatin, etoposide, mesna, 
ifosfamide
26% (n = 16) No difference. Similar OS and PFS 
among KRAS and KRAS wild-type
Schiller et al.5 E4592, completely resected pts 
randomized postoperative RT 
alone or with chemo
RT ± chemo 24% (n = 44) No difference. Similar OS and PFS 
among KRAS and KRAS wild-type
Eberhard et al.44 TRIBUTE, untreated patients with 
metastatic disease randomized to 
chemo alone or with erlotinib
Carboplatin, paclitaxel ± erlotinib 21% (n = 55) No difference. Similar OS, TTP, and ORR 
among KRAS and KRAS wild-type
Tsao et al.4 JBR.10, completely resected pts 
randomized to observation or 
chemo
Cisplatin, vinorelbine 26% (n = 117) No apparent benefit with adjuvant chemo 
in RAS mt (HR: 1.02), but chemo, RAS 
interaction test nonsignificant
Massarelli et al.45 Metastatic pts treated with EGFR 
TKI
Gefitinib or erlotinib 16% (n = 23) Nonsignificant association with poor 
response in RAS mt (p = 0.06)
Shepherd et al.29 ANITA, JBR.10, IALT, 
CALGB-9633
Platinum-based chemotherapy 19% (n = 300) No difference in OS or DFS when 
comparing RAS mt and wild-type, 
possible worse OS with chemo in 
KRAS codon 13 mt patients
Zhu et al.46 BR.21, metastatic pts randomized to 
erlotinib or placebo
Erlotinib 15% (n = 30) Lack of response in RAS mt, HR 1.67 
for RAS mt treated with erlotinib 
compared with HR 0.69 for RAS 
wild-type
Douillard47 INTEREST, metastatic pts randomized 
to gefitinib or docetaxel
Gefitinib or docetaxel 18% (n = 49) No difference between treatments  
in RAS mt
KRAS as a Prognostic Marker
Author Endpoint Comparison Number of Pts Findings
Slebos et al.1 Overall survival, disease-free 
survival
KRAS wild-type early stage 
adenocarcinomas
28% (n = 19) Shorter survival (p = 0.002), DFS  
(p = 0.038) in KRAS mt
Keohavong et al.2 Overall survival KRAS wild-type early stage 
adenocarcinomas
32% (n = 41) No difference, but with KRAS G12C/V 
having a trend (p = 0.07) toward poorer 
prognosis compared with wild-type or 
other KRAS mts
Villaruz et al.3 Overall survival, recurrence- 
free survival
KRAS wild-type predominantly early 
stage (79%) adenocarcinomas
32% (n = 318) No difference by KRAS point mutation 
in overall survival (p = 0.612) or RFS 
(p = 0.089), trend toward better OS for 
KRAS codon 13 mts  
(p = 0.052)
Tsao et al.4 Overall survival KRAS wild-type early stage NSCLC 26% (n = 117) No difference in overall survival  
(p = 0.40)
Schiller et al.5 Overall survival, progression- 
free survival
KRAS wild-type early stage NSCLC 24% (n = 44) No difference in overall survival  
(p = 0.38) or progression-free survival
Graziano et al.6 Overall survival KRAS wild-type early stage NSCLC 16% (n = 35) No difference in overall survival  
(p = 0.33)
Johnson et al.7 Overall survival KRAS, EGFR wild-type advanced 
adenocacinomas
23% (n = 241) KRAS mutant had shorter survival 
compared with KRAS/EGFR  
wild-type (p = 0.048)
Mascaux et al.8 Overall survival, meta-analysis Not consistent over studies 28 total studies KRAS mutants with shorter survival 
(HR: 1.35, 95% CI: 1.16–1.56)
RT, radiotherapy; EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-
free survival.
433Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 3, March 2015 Prognostic Impact of KRAS Mutation Subtypes
for patients with resected non–small-cell lung cancer. Patients 
harboring KRAS codon 13 mutations appear to have poorer out-
comes with adjuvant cisplatin-based chemotherapy.29 In the met-
astatic setting, KRAS mutations do not appear to independently 
predict response or resistance to chemotherapy treatments.30–33
We hypothesized that with a large number of patients 
with KRAS mutant advanced lung cancers, we would have 
sufficient power to identify any clinically meaningful dif-
ferences in outcome related to specific KRAS mutation sub-
types. To evaluate this hypothesis, we reviewed specific KRAS 
point mutation status, clinical characteristics and survival of 
patients with metastatic KRAS mutant lung cancers identified 
at our institution and then evaluated key findings in an inde-
pendent group of patients from other institutions.
METHODS
Patients
Consecutive patients with metastatic or recurrent lung 
cancers found to have a KRAS-mutation by routine molecular 
testing performed between January 2005 and January 2011 were 
included in this analysis. An electronic medical record search was 
used to identify individuals seen at Memorial Sloan-Kettering 
with a primary tumor diagnosis of lung cancer by ICD-0 code 
with available diagnostic molecular pathology reports that indi-
cated the presence of a KRAS mutation. The list was then manu-
ally reviewed to exclude patients who did not have metastatic or 
recurrent disease or a tumor diagnosis of a primary lung can-
cer. Data collection was approved by the MSKCC Institutional 
Review Board/Privacy Board. We collected clinical characteris-
tics and treatment course for all patients. Overall survival was 
defined as the time from date of advanced disease (stage IV or 
recurrent) until date of death or last follow-up. KRAS mutation 
analysis was performed before this retrospective review on avail-
able tissue by standard Sanger sequencing or by a mass spec-
trometry based mutation profiling assay.34,35
Information on mutation status and outcomes for patients 
with stage IV KRAS-mutant lung cancers identified by rou-
tine molecular sequencing during the same time period were 
collected from Dana Farber Cancer Institute, Massachusetts 
General Hospital Cancer Center, and Vanderbilt Ingram 
Cancer Center. This dataset was compiled with the intent to 
verify any significant findings in our institutional dataset.
Statistical Methods
We compared characteristics of patients with KRAS 
codon 12 and codon 13 mutant tumors using t test (for contin-
uous variables) and χ2 test (for categorical variables). Overall 
survival following diagnosis of stage IV lung cancer was esti-
mated using Kaplan–Meier methodology. Patients were fol-
lowed until death; patients alive at the end of the study were 
censored at the time of the last available follow-up. Univariate 
group comparisons were performed using log-rank tests. A 
multivariate Cox proportional hazards model was used to 
assess the independent effect of KRAS mutation type, control-
ling for potential confounding factors associated with overall 
survival in univariate analysis. All associations found signifi-
cant were validated using the external validation set.
RESULTS
Clinical Characteristics
We evaluated tumor specimens from 3357 unique patients 
with lung cancers for KRAS mutations. During that period, 677 
patients were identified to have metastatic lung cancer that 
harbored a KRAS mutation. Patient demographics are noted in 
Table 2. The majority (59%) had chemotherapy treatment details 
available. Of those with available data, there was no difference 
in the frequency of platinum-based chemotherapy, pemetrexed 
and/or bevacizumab among patients with KRAS codon 12 ver-
sus codon 13 mutations. The median line of treatment in those 
who received chemotherapy at MSKCC was 2 (range 1–9).
KRAS Mutation Subtype
The most frequent nucleotide change in tumor speci-
mens was a guanine to thymidine (G>T) seen in 366 patients. 
The prevalence of specific KRAS point mutations is summa-
rized in Figure 1. Mutations were found at codon 12 in 624 
patients (92%), and codon 13 in 53 patients (8%). Twenty-
three percent of patients (157 of 677) had transition muta-
tions (G12D, G12S, G13D, G13S). The prevalence of specific 
point mutations differed between former/current smokers and 
never-smokers (Fig. 1). Patients with transition mutations 
were more likely to be never-smokers, compared with patients 
with transversion mutations (p < 0.001). Clinical characteris-
tics were similar between patients with KRAS codon 12 versus 
13 mutations (Table 2). No concurrent EGFR mutations or 
ALK rearrangements were found in any patients.
KRAS Mutation and Survival
The median follow-up among 197 patients alive at 
the data cutoff of June 2012 was 17 months (range 1–207 
months). The median overall survival for all patients with 
KRAS mutant advanced lung cancers in our cohort was 1.2 
years (95% confidence interval [CI]: 1.2–1.4 years). Median 
overall survival for specific KRAS point mutations ranged from 
0.7 years (G13C) to 1.5 years (G12F), although no significant 
TABLE 2.  Patient Characteristics in Original KRAS Dataset
Characteristic
Total,  
n = 677
KRAS  
Codon 12, 
n = 624
KRAS  
Codon 13, 
n = 53
Age at diagnosis (stage IV)
  Median 66 66 64
  Range 31–89 31–89 44–87
Sex (%)
  Men 260 (38) 240 (38) 20 (38)
  Women 417 (62) 384 (62) 33 (62)
Smoking history (%)
  Never-smoker 48 (7) 46 (7) 2 (4)
  Former/current 
smoker
625 (92) 576 (92) 49 (93)
   Median pack year 38 35 40
   Range 1–245 1–245 7–120
  Unknown 4 2 2
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difference in survival was seen when comparing different 
KRAS point mutations (Fig. 2). There was no difference in 
outcome for patients with KRAS transition versus transversion 
mutations, with a median survival of 1.2 years for both (p = 
0.66) (Fig. 3A). No difference in overall survival was seen in 
patients with KRAS mutant lung cancers who are current or 
former-smokers (n = 625) compared with never-smokers (n = 
48), median overall survival 1.2 years (95% CI: 1.1–1.4 years) 
and 1.6 years (95% CI: 0.9–2.6), respectively (p = 0.34; Fig. 
3B). The median overall survival of patients with G12C/G12V 
mutant tumors was not different from patients with all other 
point mutations, 1.2 years for both (p = 0.74; Fig. 3C).
Patients with KRAS codon 13 mutant tumors (n = 53) 
had inferior survival compared with patients with codon 12 
mutant tumors (n = 624), median 1.1 years (95% CI: 0.8–1.3) 
and 1.3 years (95% CI: 1.1–2.4), respectively (p = 0.008; 
Fig. 3D). When comparing patients with G12D versus G13D 
mutant tumors, there was no difference in overall survival, 1.4 
and 1.2 years, respectively (p = 0.16). Among patients with 
KRAS transition mutations, there is no difference in over-
all survival when comparing smokers versus never-smokers, 
1.2 and 1.4 years, respectively (p = 0.95). Among patients with 
KRAS G12D mutations, there is no difference in outcome when 
comparing current/former-smokers to never-smokers (p = 0.66).
Multivariate Analysis
We evaluated sex, age, smoking history, and KRAS 
codon to determine impact on survival (Table 3). Sex, age, 
and KRAS codon were associated with survival in univari-
ate analysis. Men had increased risk of death, compared with 
that of women (hazard ratio [HR]: 1.28, 95% CI: 1.07–1.55; 
p = 0.008). Older age was significantly associated with 
increased risk of death, with each five additional years at 
diagnosis increasing the risk of death by 5% (HR: 1.05 for 
each added years, 95% CI: 1.01–1.10; p = 0.026). Smoking 
history did not affect outcome among those with KRAS muta-
tions (HR: 1.2, 95% CI: 0.83–1.72; p = 0.34). KRAS codon was 
associated with overall survival, with KRAS codon 13 mutant 
FIGURE 1. KRAS point mutations in the original 
KRAS dataset. A, KRAS point mutations in all patients. 
B, KRAS point mutations separated by smoking 
status.
FIGURE 2.  Overall survival by different KRAS point muta-
tions in the original KRAS dataset. n, number of patients; 
mOS, median overall survival.
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tumors having an increased risk of death, compared with 
patients with KRAS codon 12 (HR: 1.50, 95% CI: 1.11–2.04; 
p = 0.009). In a multivariate analysis controlling for age, 
sex, and smoking history, KRAS codon 13 was associated 
with shorter overall survival (HR: 1.52, 95% CI: 1.11–2.08; 
p = 0.008; Table 3).
External Validation Set
To verify the survival difference in patients with KRAS 
codon 13 versus codon 12 mutant lung cancer, we used an 
external validation set consisting of patients with KRAS 
mutant lung cancers treated at other institutions (Table 4). 
In total, 682 patients were analyzed: 354 patients from Dana 
Farber Cancer Institute, 242 patients from Massachusetts 
General Hospital, and 86 patients from Vanderbilt Ingram 
Cancer Center. In this collected set, there was no difference 
in overall survival from time of advanced disease in patients 
with KRAS codon 13 versus codon 12 mutant metastatic 
lung cancers, 1 year (95% CI: 0.7–1.5 years) versus 1.1 year 
(95% CI: 0.9–1.2 years), respectively (Fig. 4). Median fol-
low-up was similar in our dataset and the validation dataset. 
Median overall survival was longer in our dataset compared 
with the validation set, 15 versus 13 months, respectively 
(p = 0.05).
A B
C D
FIGURE 3.  Overall survival from diagnosis of stage IV cancer in the original KRAS dataset. A, Overall survival of transitions ver-
sus transversions. B, Overall survival of smokers versus never-smokers. C, Overall survival of G12C/V versus all others. D, Overall 
survival of codon 12 versus codon 13.
TABLE 3.  Univariate and Multivariate Analysis of Original 
KRAS Dataset
Univariate Analysis
Variable Survival (Yrs) HR p Value
KRAS (G13 vs. G12) 1.1 vs. 1.3 1.50 (1.11–2.04) 0.009
Sex (M vs. W) 1.0 vs. 1.4 1.28 (1.07–1.54) 0.008
Age 1.05* 0.026
Smoking (Y vs. N) 1.2 vs. 1.6 1.20 (0.83–1.72) 0.34
Multivariate Analysis
Variable HR p Value
KRAS (G13 vs. G12) 1.52 (95% CI: 1.11–2.08) 0.008
Sex (M vs. W) 1.29 (95% CI: 1.07–1.55) 0.007
Age 1.01 (95% CI: 1.001–1.02) 0.025
Smoking (Y vs. N) 1.18 (95% CI: 0.82–1.69) 0.39
HR, hazard ratio; M, men; W, women; Y, yes; N, no; CI, confidence interval.
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DISCUSSION
In this series of patients, the largest reported series of 
patients with KRAS mutant lung cancers, we validated clini-
cal prognostic factors known to be relevant in advanced lung 
cancers, but did not observe any difference in outcomes based 
on individual KRAS genotype (specific point mutation, tran-
sition versus transversion, G12 versus 13). Although others 
have noted that the specific KRAS point mutations present is 
associated with outcomes in smaller series,2 such differences 
were not observed in our group of patients. The importance of 
independent validation of observed prognostic differences is 
underscored by our identification of a difference in outcomes 
for KRAS G13 versus G12, which was not confirmed in a 
cohort of similar patients seen at three other cancer centers.
Similar to our findings, Shepherd et al.29 found that 
KRAS mutation was not prognostic in patients with early stage 
lung cancer. Other factors besides mutation subtype might be 
influencing survival. The presence of concurrent mutations 
may also influence the clinical phenotype seen with different 
KRAS mutation subtypes. LKB1 (STK11) and p53 mutations 
are seen concurrently with KRAS mutations and portend a 
poorer prognosis in patients, although the prevalence of con-
current mutations has only been assessed in small series.36–40 
Preclinical data indicate that loss of LKB1 leads to a more 
aggressive tumor phenotype, with short tumor latency and 
greater rate of metastasis.37 The presence of concurrent muta-
tions may also have treatment implications as preclinical data 
suggest concurrent LKB1 inactivation alters downstream sig-
naling and sensitivity to mammalian target of rapamycin and 
MEK inhibition.41–43 More clearly characterizing the frequency 
of concurrent mutations and understanding their correlation 
with clinical behavior will be helpful in further defining the 
prognosis of patients with KRAS mutant lung cancers.
There are limitations to our analysis. All patients were 
identified based upon molecular testing at a single institution 
during a time (beginning in 2005) in which molecular analysis 
was not broadly performed, and therefore these patients may 
not be representative of a general population. They received 
diverse treatment and the vast majority did not receive any 
KRAS-directed targeted therapy. Patients with different KRAS 
mutation subtypes may respond differently to chemotherapy, 
and our analysis was not powered to identify any predictive 
effects of KRAS mutation subtype. Performance status, a 
powerful prognostic factor, was not included in our analysis. 
In addition, even with a larger dataset, we are limited in our 
ability to make conclusions regarding KRAS mutation subsets 
that are rare. Due to these limitations, we attempted to validate 
our findings in an external dataset, in which we did not find 
a difference in survival when comparing patients with KRAS 
G12 versus G13 mutant tumors. Further validation would be 
needed to draw definitive conclusions regarding the prognos-
tic value of KRAS mutation subtype.
KRAS mutation subtype does not appear to be associ-
ated with overall survival from the diagnosis of lung cancer. 
Investigation into other areas such as variable gene expression 
and identifying concurrent mutations may identify potential 
molecular prognostic markers in patients with KRAS mutant 
lung cancers.
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